CytomX Therapeutics is a clinical-stage biopharmaceutical company developing oncology therapies using its PROBODY technology platform. The platform utilizes conditionally activated, masked biologics to reduce binding to targets until proteases in the tumor microenvironment remove the mask, aiming to optimize the therapeutic index. The company's pipeline includes antibody-drug conjugates (ADCs), T-cell engagers, and cytokines. Its most advanced program, varsetatug masetecan (Varseta-M), is an investigational ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload licensed from AbbVie. Varseta-M is currently in Phase 1 clinical development, initially focused on late-line metastatic colorectal cancer, with plans to expand to other EpCAM-expressing solid tumors. The company also has a second clinical program, CX-801, in Phase 1 development. CytomX serves the global oncology market, focusing on unmet needs in solid tumors such as colorectal, gastric, pancreatic, ovarian, and breast cancers.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage cytomx.com
Sector Healthcare IR page ir.cytomx.com
Tags
oncology, antibody-drug conjugates, t-cell engagers, cytokines, colorectal cancer, solid tumors, conditional activation, masked biologics, topoisomerase-1 inhibitors, epcam targeting, PROBODY, varsetatug masetecan, Varseta-M, CX-801, KORJUNY
Press page —

Metrics

Valuation  
Market cap $ 592.973M
Market cap (USD) $ 592.973M
P/E -6.94
PEG —
P/BV 2.08
P/S 42.27
P/OCF -11.81
P/FCF -11.68
Dividend yield —
Turnover / mcap —
Returns  
ROE -17.5%
ROI -20.1%
ROIC -19.4%
Profit margin -22.8%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -72.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 76.201M 138.103M 101.214M 53.163M 69.573M 100.362M 57.489M 59.502M 71.623M 15.043M 7.712M 5.077M
Net profit -17.368M 31.869M -569K -99.317M -83.609M -32.885M -102.238M -84.604M -43.099M -58.9M -35.374M -30.31M
Free cash flow -75.807M -86.541M -56.875M -112.528M -120.64M 2.95M -143.977M -79.309M 168.814M -4.208M -29.009M 30.139M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 4.26 1.03 1.55 1.6 4.33 6.55 8.31 15.1 21.11 10.99 20.87 —
Price performance 12m 3.14 -0.34 -0.03 -0.63 -0.34 -0.21 -0.45 -0.28 0.92 -0.47 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 2.16M 10.1M 97,000 13,000 798,000 790,000 36M 3.43M 3.1M 2.01M
↳ YoY growth +190.2% +369.6% -99.0% -86.6% +6,038.5% -1.0% +4,455.2% -90.5% -9.6% -35.1%
↳ 5y CAGR -63.0% +1.4% -18.2% +28.8% +104.1% +198.9% +20.3%
Lease liabilities (USD) — — — 27.7M 24.9M 21.7M 18.1M 14M 9.39M 4.24M
Cash and deposits (USD) 105M 178M 248M 188M 192M 206M 194M 17.2M 38.1M 12.7M
Right-of-use assets (USD) — — — 25.4M 22.5M 19.4M 15.9M 12.2M 8.14M 3.4M
Cash flow detail
Operating cash flow (USD) -2.03M 170M -75.5M -140M 5.26M -119M -111M -56M -86.2M -75.6M
Purchases of property, plant and equipment (USD) -2.18M -1.56M -3.79M -3.5M -2.31M -1.61M -1.74M -840,000 -310,000 -220,000
Change in receivables (cash effect) (USD) -1.79M -7.98M 10M 84,000 -785,000 8,000 -35.2M 32.6M 329,000 1.09M
Change in payables (cash effect) (USD) 1.77M -2.44M 261,000 -374,000 -857,000 -139,000 68,000 -1.43M -297,000 221,000
Income taxes paid (cash effect) (USD) — — — -13.1M 0.00 0.00 — — — —
Share-based compensation (USD) 10.1M 11.3M 16.9M 19.1M 14.8M 13.2M 13.1M 8.56M 7.67M 6.3M
Operating cash flow before change in receivables (USD) -245,000 178M -85.6M -141M 6.04M -119M -75.6M -88.6M -86.6M -76.7M
Free cash flow (OCF - PPE - intangibles) (USD) -4.21M 169M -79.3M -144M 2.95M -121M -113M -56.9M -86.5M -75.8M
Income detail
Research and development expense (USD) 54.8M 92.3M 104M 132M 113M 114M 112M 77.7M 83.4M 68.7M
↳ 5y CAGR +57.0% +36.0% +31.8% +15.8% +3.9% -5.6% -8.7% -9.5%
Total comprehensive income (USD) -58.9M -43.2M -84.6M -102M -33M -83.8M -99.1M -484,000 31.8M -17.3M
Comprehensive income to owners (USD) -58.9M -43.2M -84.6M -102M -33M -83.8M -99.1M -484,000 31.8M -17.3M
Reported Mar 2, 2017 Mar 7, 2018 Feb 27, 2019 Feb 27, 2020 Mar 1, 2022 Mar 1, 2022 Mar 27, 2023 Mar 11, 2024 Mar 6, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 5, 2026 at 4:15 PM EST

Download PDF

  • Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer -

  • Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 -

  • Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study in 2L mCRC expected to be initiated by year-end -

  • Phase 1 Varseta-M monotherapy expansion cohorts for gastric and gastroesophageal junction (GEJ) cancer, EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) in progress -

  • Company to host conference call and webcast today at 5 p.m. ET / 2 p.m. PT -

EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced Q3 2026 financial results and provided a business update.

“Varseta-M is a first-in-class EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, intentionally designed to improve the standard of care for patients with colorectal and other cancers. At CytomX, we are highly focused on rapidly advancing monotherapy Varseta-M towards a first registrational study in colorectal cancer,” said Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics.

“Additionally, the Varseta-M development program continues to broaden, including an ongoing combination study with bevacizumab in mCRC and the initiation of Phase 1 expansion cohorts in gastric and gastroesophageal junction cancer, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer. Our integrated strategy is intended to urgently advance Varseta-M for the maximum benefit of cancer patients.”

Pipeline Program Updates:

Varsetatug masetecan (EpCAM PROBODY Topo-1 ADC, CX-2051)

  • Varseta-M Monotherapy CRC:

  • Announced FDA Fast Track Designation for Varseta-M for relapsed/refractory metastatic colorectal cancer in August.

  • A Phase 1 monotherapy mCRC data update, including dose selection and potential registrational strategy, expected in January 2027.

  • Potential to initiate first registrational study for Varseta-M monotherapy in mCRC in 1H 2027.

  • Varseta-M CRC Combinations:

  • A Phase 1 combination study of Varseta-M and bevacizumab is ongoing. Dose finding is enrolling late-line patients, with plans to focus on 2L and 3L mCRC once a go-forward dose and schedule are selected. Initial clinical data is anticipated in 1H 2027.

  • A Phase 1/2 combination study evaluating Varseta-M administered with bevacizumab, 5-fluorouracil, and leucovorin in 2nd line mCRC patients is planned to initiate by the end of 2026.

  • Varseta-M Expansion into Other GI-related Indications:

  • Varseta-M monotherapy Phase 1 expansion cohort enrollment in gastric and gastroesophageal junction (GEJ) cancer, EpCAM-selected pancreatic ductal adenocarcinoma (PDAC), and EpCAM-selected biliary tract cancer (BTC) was initiated.

CX-801 (PROBODY Interferon alpha-2b)

  • CytomX’s second masked pipeline product candidate, CX-801, continues enrollment in the ongoing Phase 1 study in advanced melanoma. The CX-801 monotherapy dose escalation portion of the study has reached the fourth dose level.

  • CX-801 monotherapy has been generally well tolerated at dose levels exceeding the approved dose of unmasked IFNα2b.1

  • The ongoing Phase 1 dose escalation of CX-801 in combination with KEYTRUDA® (pembrolizumab) continues enrollment and has cleared the third dose level.

  • Initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma is expected in the first half of 2027.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Q3 2026 Financial Results:

CytomX ended Q3 2026 with $348.0 million of cash, cash equivalents and investments with expected cash runway into the second half of 2028. Cash, cash equivalents and short-term investments totaled $330.3 million as of Q2 2026.

Total revenue was $1.7 million for the quarter ended September 30, 2026, compared to $6.0 million for quarter ended September 30, 2025. The decrease in revenue was driven primarily by the completion of the Company’s performance obligation in the Astellas collaboration which concluded in the second quarter of 2026.

Total operating expense for the quarter ended September 30, 2026 was $25.2 million compared to $21.7 million for the quarter ended September 30, 2025, an increase of $3.5 million.

Research and development expenses increased by $1.2 million during the quarter ended September 30, 2026, to $16.5 million compared to $15.3 million for the quarter ended September 30, 2025. Research and development expenses increased primarily due to increased personnel related expenses, partially offset by lower Varseta-M spend due to the timing of manufacturing activities.

General and administrative expenses increased by $2.3 million during the quarter ended September 30, 2026, to $8.7 million, compared to $6.4 million for the quarter ended September 30, 2025. Increased general and administrative expenses were primarily driven by increased personnel related expenses, consulting expenses and an increase in rent expense during the Company’s transition to its new Emeryville headquarters.

About CytomX Therapeutics, Inc. CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated antibody drug conjugate armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Regeneron. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

CytomX Therapeutics Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond CytomX’s control, and may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements, including those related to the future potential of partnerships or collaboration agreements and projected cash runway. These forward-looking statements include, but are not limited to, statements relating to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product candidates, including varsetatug masetecan (Varseta-M) and CX-801, the potential benefits or applications of CytomX’s PROBODY® therapeutic platform, CytomX's planned interactions with the U.S. Food and Drug Administration and the ability to align on a potential registrational study design and regulatory pathway for Varseta-M, the anticipated initiation of a potential registrational study and the Phase 1/2 combination study, the expansion of Varseta-M into additional indications, CytomX’s or its collaborative partners’ ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of Varseta-M and CX-801 and the timing of initial and ongoing data availability for CytomX’s clinical trials, including Varseta-M and CX-801, and other development milestones. Accordingly, you should not place undue reliance on these forward-looking statements. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel PROBODY® therapeutic technology; uncertainties around CytomX’s ability to raise sufficient funds to carry out its planned research and development; the early stage of CytomX’s clinical trial product candidates, which are in the initial stages of clinical development, and its other product candidates, which are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the possibility that the results of preclinical research and early clinical trials, including initial Varseta-M clinical trial results, may not be predictive of future results; the risk that interim or preliminary clinical data may change as more patient data become available; the possibility that CytomX’s clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; the possibility that CytomX may not be able to realize the full potential of its collaborations; CytomX’s dependence on the success of Varseta-M and CX-801; CytomX’s reliance on third parties for the manufacture of CytomX’s product candidates; possible regulatory developments in the United States and foreign countries, including China and the European Union; and the risk that CytomX may incur higher costs than expected for research and development. Additional applicable risks and uncertainties include those relating to CytomX’s preclinical research and development, clinical development, and other risks identified under the heading “Risk Factors” included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026 and in CytomX’s subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. Except as required by applicable law, CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc. All other trademarks are the properties of their respective owners.

Company Contact: Chris Ogden SVP, Chief Financial Officer [email protected]

Investor Contact: Precision AQ Stephanie Ascher [email protected]

Media Contact: Precision AQ Colleen Ketchum [email protected]

| CYTOMX THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (in thousands) |

| |

| | | September 30, | | | December 31, | |

| | | 2026 | | | 2025 | | |

| | | (unaudited) | | | (1) | | |

| Assets | | | | | | |

| Current assets: | | | | | | |

| Cash and cash equivalents | | $ | 33,963 | | | $ | 12,667 | | |

| Short-term investments | | | 314,017 | | | | 124,385 | | |

| Restricted cash | | | 917 | | | | — | | |

| Accounts receivable | | | 501 | | | | 2,013 | | |

| Prepaid expenses and other current assets | | | 6,650 | | | | 4,856 | | |

| Total current assets | | | 356,048 | | | | 143,921 | | |

| Property and equipment, net | | | 2,518 | | | | 1,304 | | |

| Intangible assets, net | | | 328 | | | | 438 | | |

| Goodwill | | | 949 | | | | 949 | | |

| Restricted cash | | | 610 | | | | 1,527 | | |

| Operating lease right-of-use asset | | | 3,675 | | | | 3,396 | | |

| Other assets | | | 551 | | | | 31 | | |

| Total assets | | $ | 364,679 | | | $ | 151,566 | | |

| Liabilities and Stockholders' Equity | | | | | | |

| Current liabilities: | | | | | | |

| Accounts payable | | $ | 1,138 | | | $ | 1,301 | | |

| Accrued liabilities | | | 16,453 | | | | 14,197 | | |

| Operating lease liabilities - short-term | | | 526 | | | | 4,240 | | |

| Deferred revenue, current portion | | | 27,415 | | | | 26,877 | | |

| Total current liabilities | | | 45,532 | | | | 46,615 | | |

| Deferred revenue, net of current portion | | | 25,864 | | | | 1,590 | | |

| Operating lease liabilities - long term | | | 3,862 | | | | — | | |

| Other long-term liabilities | | | 4,533 | | | | 4,353 | | |

| Total liabilities | | | 79,791 | | | | 52,558 | | |

| Commitments and contingencies | | | | | | |

| Stockholders' equity: | | | | | | |

| Convertible preferred stock | | | — | | | | — | | |

| Common stock | | | 2 | | | | 2 | | |

| Additional paid-in capital | | | 1,056,062 | | | | 810,844 | | |

| Accumulated other comprehensive income (loss) | | | (315 | ) | | | 111 | | |

| Accumulated deficit | | | (770,861 | ) | | | (711,949 | ) | |

| Total stockholders' equity | | | 284,888 | | | | 99,008 | | |

| Total liabilities and stockholders' equity | | $ | 364,679 | | | $ | 151,566 | | |

| | | | | | | |

(1) The condensed balance sheet as of December 31, 2025 was derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

| CYTOMX THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (in thousands, except share and per share data) (Unaudited) |

| |

| | Three Months Ended | | | Nine Months Ended | |

| | September 30, | | | September 30, | |

| | 2026 | | | 2025 | | | 2026 | | | 2025 | | |

| Revenues | $ | 1,688 | | | $ | 5,963 | | | $ | 13,365 | | | $ | 75,538 | | |

| Operating expenses: | | | | | | | | | | | | |

| Research and development | | 16,480 | | | | 15,304 | | | | 53,316 | | | | 47,493 | | |

| General and administrative | | 8,710 | | | | 6,427 | | | | 27,004 | | | | 22,477 | | |

| Total operating expenses | | 25,190 | | | | 21,731 | | | | 80,320 | | | | 69,970 | | |

| Income (loss) from operations | | (23,502 | ) | | | (15,768 | ) | | | (66,955 | ) | | | 5,568 | | |

| Interest income | | 3,271 | | | | 1,592 | | | | 7,918 | | | | 3,725 | | |

| Other income | | 294 | | | | 5 | | | | 305 | | | | 33 | | |

| Income (loss) before income taxes | | (19,937 | ) | | | (14,171 | ) | | | (58,732 | ) | | | 9,326 | | |

| Provision for income taxes | | 61 | | | | 58 | | | | 180 | | | | 184 | | |

| Net income (loss) attributable to common stockholders | | (19,998 | ) | | | (14,229 | ) | | | (58,912 | ) | | | 9,142 | | |

| Other comprehensive income (loss): | | | | | | | | | | | | |

| Unrealized gain (loss) on investments, net of tax | | (119 | ) | | | 71 | | | | (426 | ) | | | 77 | | |

| Total comprehensive income (loss) | $ | (20,117 | ) | | $ | (14,158 | ) | | $ | (59,338 | ) | | $ | 9,219 | | |

| | | | | | | | | | | | | |

| Net income (loss) per share: | | | | | | | | | | | | |

| Basic | $ | (0.09 | ) | | $ | (0.09 | ) | | $ | (0.29 | ) | | $ | 0.07 | | |

| Diluted | $ | (0.09 | ) | | $ | (0.09 | ) | | $ | (0.29 | ) | | $ | 0.07 | | |

| Weighted average common shares used to compute net income (loss) per share | | | | | | | | | | | | |

| Basic | | 219,106,651 | | | | 165,004,291 | | | | 205,259,594 | | | | 127,352,366 | | |

| Diluted | | 219,106,651 | | | | 165,004,291 | | | | 205,259,594 | | | | 128,859,852 | | |

| |

1 Merck & Co., Inc. (2018). Sylatron (peginterferon alfa-2b) prescribing information. U.S. Food and Drug Administration

Primary Logo

Source: CytomX Therapeutics Inc.

November 2, 2026 at 8:00 AM EST

Download PDF

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November.

Guggenheim 3rdAnnual Healthcare Innovation Conference Date: Monday, November 9, 2026 Fireside Chat: 3:30 p.m. ET Location: Boston, MA

Jefferies Global Healthcare Conference in London Date: Wednesday, November 18, 2026 Fireside Chat: 8:30 a.m. GMT Location: London, UK

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

**About CytomX Therapeutics, Inc.**CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X**(formerly Twitter)**.

Company Contact: Chris Ogden SVP, Chief Financial Officer [email protected]

Investor Contact: Precision AQ Stephanie Ascher [email protected]

Media Contact: Precision AQ Colleen Ketchum [email protected]

Primary Logo

October 29, 2026 at 8:00 AM EDT

Download PDF

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call hereand are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.

About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X(formerly Twitter).

Company Contact: Chris Ogden SVP, Chief Financial Officer [email protected]

Investor Contact: Precision AQ Stephanie Ascher [email protected]

Media Contact: Precision AQ Colleen Ketchum [email protected]

Primary Logo

Prompts

CytomX Therapeutics, Inc. (ticker CTMX), listed in United States.

ETFs Holding CytomX Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FMED 0.73% 112,069 $ 376.552K Aug 31, 2026
CANC 0.38% 241,337 $ 810.892K Aug 31, 2026
FORH 0.34% 17,710 $ 66.413K Jun 30, 2026
FFSM 0.06% 305,459 $ 946.923K Jul 31, 2026
RESM 0.02% 202 $ 757.50 Jun 30, 2026
MSSM 0.00% 9,722 $ 32.666K Aug 31, 2026
DXUV 0.00% 52,438 $ 106.974K Nov 12, 2026
DFAS 0.00% 124,826 $ 254.645K Nov 12, 2026
DFAU 0.00% 24,102 $ 49.168K Nov 12, 2026
DCOR 0.00% 39,150 $ 79.866K Nov 12, 2026
DFAC 0.00% 57,225 $ 116.739K Nov 12, 2026
AVSC 0.00% 66,682 $ 132.364K Nov 16, 2026